News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
117,538 Results
Type
Article (7666)
Company Profile (30)
Press Release (109841)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (33617)
Career Advice (230)
Deals (5309)
Drug Delivery (13)
Drug Development (10156)
Employer Resources (14)
FDA (3364)
Job Trends (3257)
News (54681)
Policy (5970)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
Academia (745)
Academic (1)
Accelerated approval (1)
Allergies (19)
Alliances (10642)
ALS (17)
Alzheimer's disease (296)
Antibody-drug conjugate (ADC) (65)
Approvals (3481)
Artificial intelligence (112)
Autoimmune disease (15)
Automation (22)
Bankruptcy (36)
Best Places to Work (2541)
BIOSECURE Act (1)
Biosimilars (30)
Biotechnology (21)
Bladder cancer (42)
Brain cancer (8)
Breast cancer (137)
Cancer (916)
Cardiovascular disease (47)
Career advice (213)
Career pathing (2)
CAR-T (47)
CDC (3)
Celiac Disease (1)
Cell therapy (112)
Cervical cancer (14)
Clinical research (8121)
Collaboration (372)
Company closure (1)
Compensation (16)
Complete response letters (5)
COVID-19 (714)
CRISPR (21)
C-suite (113)
Cystic fibrosis (30)
Data (940)
Denatured (3)
Depression (9)
Diabetes (41)
Diagnostics (3405)
Digital health (9)
Diversity (1)
Diversity, equity & inclusion (3)
Drug discovery (54)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (29)
Earnings (10388)
Editorial (7)
Employer branding (3)
Employer resources (12)
Events (12469)
Executive appointments (157)
FDA (3841)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (2)
Funding (219)
Gene editing (35)
Generative AI (8)
Gene therapy (96)
GLP-1 (155)
Government (1037)
Grass and pollen (3)
Guidances (59)
Healthcare (2765)
HIV (13)
Huntington's disease (15)
IgA nephropathy (5)
Immunology and inflammation (26)
Immuno-oncology (5)
Indications (22)
Infectious disease (770)
Inflammatory bowel disease (21)
Influenza (30)
Intellectual property (28)
Interviews (32)
IPO (1694)
IRA (3)
Job creations (838)
Job search strategy (196)
JPM (13)
Kidney cancer (1)
Labor market (9)
Layoffs (59)
Leadership (2)
Legal (1210)
Liver cancer (13)
Longevity (1)
Lung cancer (140)
Lymphoma (75)
Machine learning (11)
Management (4)
Manufacturing (166)
MASH (11)
Medical device (1902)
Medtech (1907)
Mergers & acquisitions (3750)
Metabolic disorders (118)
Multiple sclerosis (11)
NASH (2)
Neurodegenerative disease (52)
Neuropsychiatric disorders (8)
Neuroscience (434)
NextGen: Class of 2026 (990)
Non-profit (670)
Now hiring (15)
Obesity (61)
Opinion (43)
Ovarian cancer (19)
Pain (12)
Pancreatic cancer (25)
Parkinson's disease (29)
Partnered (10)
Patents (50)
Patient recruitment (32)
Peanut (10)
People (10309)
Pharmaceutical (6)
Pharmacy benefit managers (1)
Phase 1 (2421)
Phase 2 (3171)
Phase 3 (3141)
Pipeline (816)
Policy (17)
Postmarket research (412)
Preclinical (1372)
Press Release (18)
Prostate cancer (42)
Psychedelics (6)
Radiopharmaceuticals (41)
Rare diseases (109)
Real estate (2062)
Recruiting (4)
Regulatory (4391)
Reports (9)
Research institute (699)
Resumes & cover letters (24)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (16)
Series A (39)
Series B (19)
Sickle cell disease (9)
Special edition (4)
Spinal muscular atrophy (37)
Sponsored (7)
Startups (684)
State (1)
Stomach cancer (3)
Supply chain (25)
Tariffs (10)
The Weekly (6)
Vaccines (104)
Venture capital (17)
Weight loss (37)
Women's health (12)
Date
Last 7 days (72)
Last 30 days (300)
Last 365 days (3957)
2026 (382)
2025 (4031)
2024 (5199)
2023 (5932)
2022 (9603)
2021 (10070)
2020 (9774)
2019 (7029)
2018 (5491)
2017 (5689)
2016 (5855)
2015 (6447)
2014 (5144)
2013 (4507)
2012 (4847)
2011 (4912)
2010 (4282)
Location
Africa (145)
Alabama (11)
Alaska (1)
Arizona (52)
Arkansas (2)
Asia (7299)
Australia (1159)
California (1344)
Canada (418)
China (94)
Colorado (68)
Connecticut (55)
Delaware (59)
Europe (15779)
Florida (213)
Georgia (27)
Idaho (6)
Illinois (96)
India (11)
Indiana (83)
Iowa (3)
Japan (106)
Kansas (25)
Kentucky (7)
Louisiana (4)
Maine (27)
Maryland (161)
Massachusetts (965)
Michigan (121)
Minnesota (59)
Missouri (61)
Montana (9)
Nebraska (3)
Nevada (8)
New Hampshire (10)
New Jersey (580)
New Mexico (8)
New York (445)
North Carolina (219)
North Dakota (1)
Northern California (600)
Ohio (65)
Oklahoma (4)
Oregon (5)
Pennsylvania (191)
Rhode Island (12)
South America (198)
South Carolina (7)
Southern California (545)
Tennessee (29)
Texas (391)
United States (5480)
Utah (87)
Vermont (1)
Virginia (22)
Washington D.C. (7)
Washington State (122)
Wisconsin (22)
117,538 Results for "seventh wave laboratories".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way.
February 2, 2026
·
3 min read
·
Heather McKenzie
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Weight loss
Wave Soars on Early Results for Obesity Treatment That Could ‘Disrupt’ the Landscape
Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, with 4% fat reduction after three months, beating Novo Nordisk’s semaglutide at a similar time point.
December 8, 2025
·
1 min read
·
Dan Samorodnitsky
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
Pfizer deals again in obesity space as Wave and Structure drop splashy weight loss results; what CDER Director Richard Pazdur’s sudden retirement means for biopharma; neuro diseases take center stage at CTAD; and more.
December 10, 2025
·
1 min read
·
Heather McKenzie
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
Wave’s RNA editor resulted in protein levels that were “exceedingly close” to what investors were expecting, but nevertheless fell short of that bar, according to analysts at Truist Securities.
September 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
SONOMOTION ANNOUNCES FDA CLEARANCE FOR ITS BREAK WAVE™ LITHOTRIPSY DEVICE FOR TREATMENT OF KIDNEY STONES
January 22, 2026
·
2 min read
Press Releases
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
February 2, 2026
·
7 min read
Press Releases
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
1 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
·
4 min read
Duchenne muscular dystrophy
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.
March 26, 2025
·
3 min read
·
Heather McKenzie
1 of 11,754
Next
